Skip to main content
. Author manuscript; available in PMC: 2024 Oct 10.
Published in final edited form as: Immuno. 2024 Mar 3;4(1):108–124. doi: 10.3390/immuno4010007

Figure 1.

Figure 1.

The multiplexed immunoassay (MIA) differentiates SARS-CoV-2 serological status. (A) Graphical representation of MIA process created with BioRender.com and Adobe Illustrator. (B) MIA of samples collected in Hawaii. One-way ANOVA multiple comparison analysis. Grey lines indicate BSA cut-offs, and black lines indicate antigen cut-offs. (C) Principal component analysis of samples collected in Hawaii. Calculations completed in GraphPad Prism, Principal component analysis. * < 0.5, ** < 0.01, **** < 0.0001. 2°Ab-PE = phycoerythrin-coupled secondary antibody, NC = negative controls (n = 10), N = naïve (n = 7), C = convalescent (n = 7), PD1 = post-dose 1, PD2 = post-dose 2. Wu-1 Trimer = Wuhan Hu1 strain spike trimer, Alpha-S1 = SARS-CoV-2 Alpha strain spike domain 1, Beta S1 + S2 = SARS-CoV-2 Beta strain spike domains 1 + 2, Wu-1 NP = Wuhan Hu1 strain nucleocapsid protein, NL63 S1 = hCoV-NL63 spike domain 1, DENV-2E = Dengue virus serotype 2 envelope protein, DENV-2 NS1 = Dengue virus serotype 2 nonstructural protein 1.